Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer

Bratislava Medical Journal

Volumn 115, Issue 3, 2014, Pages 171-174

  Aydin, O ^a   Eren, E ^b   Yalcinkaya, S ^c   Yilmaz, N ^a   Eroglu, M ^c   Ellidag, H Y ^a  

^a Central laboratories of Antalya Education and Research Hospital of Ministry of Health   (Turkey)

^b Antalya Public Health Center of Ministry of Health   (Turkey)

^c Neurology clinic of Antalya Education and Research Hospital of Ministry of Health   (Turkey)

Author keywords

Aldosterone; Parathyroid hormone; Prostate carcinoma; Prostate specific antigen; Vitamin D

Indexed keywords

PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

AGED; ARTICLE; BLOOD; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR;

AGED; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84894631503     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_036     Document Type: Article

References (19)

1. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990; 10: 1307-1311.
2. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003; 14: 423-430.
3. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000; 9: 265-270.
4. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992; 52: 515-520.
5. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
6. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985; 5: 307-309.
7. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006; 9: 24-28.
8. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
9. Schwartz GG. Vitamin D and the Epidemiology of Prostate Cancer. Semin Dial 2005; 18: 276-289.
10. Fraser DR. Exploration of possible mechanisms linking vitamin D status and dietary calcium to prostate cancer. Br J Nutr 2007; 97: 596-597.
11. Ritchie CK, Thomas KG, Andres LR, Tindall DJ, Fitzpatrick LA. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997; 30: 183-187.
12. Lia J, Schnieder A, Datta NS, McKauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006; 77: 9065-9073.
13. Gomes RR Jr, Buttke P, Paul EM, Sikes RA. Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin Exp Metastasis 2009; 26 (7): 641-651.
14. Skinner HG, Schwartz GG. The Relation of Serum Parathyroid Hormone and Serum Calcium to Serum Levels of Prostate-Specific Antigen: A Population-Based Study. Cancer Epidemiol Biomarkers Prev 2009; 18 (11): 2869-2873.
15. Kim WT, Choi YD, Park C et al. Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia. Prostate 2011; 71 (11): 1210-1215.
16. McCarty MF. Medical Parathyroid hormone may be a cancer promoter {ETH} an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Medical Hypotheses 2000; 54: 475-482.
17. Dusso AS, Finch J, Brown A et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991; 72: 157-164 18. Losel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 2002; 67: 493-498.
18. Losel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 2002; 67: 493-498
19. + channels (IKca1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 2009; 28: 1792-1806.